MESO

Mesoblast Limited

2.08 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Mesoblast Limited stock is up 17.51% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 February’s closed higher than January.

About Mesoblast Limited

Mesoblast Limited offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection. The company has strategic partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd. and Grünenthal.